SCHEMBL2087745

SCHEMBL2087745

COCCCOc1cc(C(=O)NC2CC2)ccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.49
HPGD P15428 2/20 0.48
F10 P00742 4/20 0.47
UTS2R Q9UKP6 1/20 0.47
CNR2 P34972 2/20 0.47
MAPK14 Q16539 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
ACHE P22303 1/20 0.45
DRD2 P14416 1/20 0.45
HTR2A P28223 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RIPK2 O43353 1/20 0.45
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89015 0.86 CNR2 (0.55) HPGDCNR2MAPK14MEN1KMT2A
SCHEMBL90498 0.86 CNR2 (0.61) F10CNR2MAPK14MEN1KMT2A
SCHEMBL90493 0.83 HTR7 (0.50) HPGDCNR2MAPK14MAPK1RAB9A
SCHEMBL3374286 0.83 FABP4 (0.48) HPGDKDM4EPOLB
SCHEMBL3369968 0.78 HDAC6 (0.52) HPGDKDM4EMEN1POLBKMT2A
SCHEMBL89853 0.76 CYP2C9 (0.39) HPGDUTS2RMEN1POLBMAPT
SCHEMBL10381364 0.76 FABP4 (0.49) HPGDKDM4EMEN1POLBMAPT
SCHEMBL17732270 0.75 PDE4D (0.47) F10
SCHEMBL8238436 0.75 MAPK14 (0.52) F10CNR2MAPK14MEN1POLB
SCHEMBL2086320 0.74 KMT2A (0.44) KDM4EMEN1POLBMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163773-B2 Organic compounds NOVARTIS AG (CH) 2012-04-24 US disclosed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP disclosed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 LRRK2 3549/4885HPGD 802/4885F10 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.